Christopher Schrodt
Psychiatry · Louisville, KYNPI 1730309188
Payments from drug & device makers
Across 133 payments — averaging $12.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$540
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$223
- Supernus Pharmaceuticals, Inc.$215
- Ironshore Pharmaceuticals Inc.$133
- Takeda Pharmaceuticals U.S.A., Inc.$131
- Johnson & Johnson$131
- plus $233 from 9 others
What the payments were for
- Food & beverage$1,55497%
- Education$523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,606 in reported general payments places this provider in the 70th percentile of 348 psychiatry providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 52 | $439,572 |
| CaplytaLumateperone Tosylate | 24 | $56,511 |
| AuvelityDextromethorphan Hbr/Bupropion | 43 | $45,133 |
| RexultiBrexpiprazole | 23 | $31,637 |
| TrintellixVortioxetine Hydrobromide | 23 | $21,135 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $11,180 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 126 | $6,676 |
| Lurasidone Hcl | 27 | $6,589 |
| Bupropion XlBupropion Hcl | 260 | $5,934 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 113 | $3,708 |
| Duloxetine Hcl | 144 | $3,217 |
| Quetiapine Fumarate | 104 | $2,334 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $1,846 |
| Buspirone Hcl | 31 | $1,829 |
| Olanzapine | 27 | $1,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $223 | $56,51124 claims |
| Axsome Therapeutics, Inc.Auvelity | $22 | $45,13343 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $131 | $32,31447 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14 | $31,63723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Louisville
- Rifaat El-MallakhLouisville$1.7M
- Robert StewartLouisville$651K
- Ali FarooquiLouisville$393K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Kevin BaysLouisville$9K
- Terry HaganLouisville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.